NEW YORK (GenomeWeb News) – ChondroGene today said that second-quarter revenue slid 42 percent as R&D spending rose by nearly one-third and net losses swelled 160 percent.
 
Total receipts for the three months ended June 30 declined to CA$873,020 ($781,020) from CA$1.5 million year over year. ChondroGene said the current quarter’s results comprise a CA$679,228 amortized one-time payment from Pfizer as part of an R&D alliance penned in 2004 and around CA$194,000 in fee and service revenue.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Cancer researcher Alan Rabson has died at 92, the New York Times reports.

As the National Guideline Clearinghouse goes dark, the ECRI Institute says it will pick up the slack.

In Genome Research this week: sequencing method examines proteins parasite uses to evade immune system, L1 insertions in cancer, and more.

The Atlantic reports on private Facebook support groups for people who receive unexpected parentage results from direct-to-consumer genetic tests.